National, Observational Registry for Comprehensive Follow-up of All Implementations of the AVEIR VR LP Device in France (France LEADLESS)
Although the idea of a leadless pacemaker was first proposed in the 1970s to eliminate the probes, pockets and connectors required by conventional cardiac procedures and the associated complications, the first devices were not developed until the late 2010s. Leadless pacemakers can also improve patient comfort by replacing surgery with a percutaneous procedure, eliminating the mass and scar visible at the implantation site of a conventional pacemaker, and eliminating the need for activity restrictions to prevent dislodgement after implantation of a conventional lead.

The AVEIR VR LP leadless pacemaker was CE marked in July 2023 and will be implanted in patients in Europe.

The objective of this national registry is to evaluate the safety and performance of the AVEIR VR LP system in a population of patients indicated for implantation of a VVI(R) pacemaker in France. This registry will also allow the collection of patient characteristics and indications under normal conditions of use.
- EligibilityCriteria: Inclusion Criteria:  Patient implanted with an AVEIR VR LP device Patient over 18 years old Patient informed of the nature of the study, agrees to participate in the study  Exclusion Criteria:  Patient under 18 years of age Patient refusing to participate in the study - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients will be included in cardiology departments participating in the study. The study may be offered to any patient undergoing an implantation of leadless pacemaker using AVEIR VR LP device in France. - SamplingMethod: Non-Probability Sample